Active ingredientGalidesivirCat. No. P-G012-001CAS 249503-25-1Family · Pharmaceutical analytical standards
Galidesivir
A broad-spectrum antiviral adenosine analogue, originally intended for hepatitis C and then studied from the 2010s onwards against Ebola, Marburg, Zika and COVID-19; it has remained an investigational drug. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?In rodent and monkey studies it protected against filoviruses such as Ebola and Marburg even when given up to 48 hours after infection.
Go to the active ingredient →Active ingredientGalidesivirCat. No. P-G012-001CAS 249503-25-1
Active ingredientGalidesivir DiHClCat. No. P-G012-002CAS 1373208-51-5
Isotopically labelledGalidesivir-13C5Cat. No. P-G012-003
ImpurityGalidesivir TriphosphateCat. No. P-G012-004CAS 1467740-78-8No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.